期刊文献+

盐酸苯达莫司汀有关物质结构鉴定 被引量:2

Identification of the related substances in bendamustine hydrochloride
下载PDF
导出
摘要 建立HPLC法对盐酸苯达莫司汀的有关物质进行分析,检测出2个有关物质IMP01和IMP02;通过LC-MS/MS法推测出2个有关物质的结构,并合成制备得到2个有关物质单体,根据Q-TOF/MS以及NMR结果综合解析确证了两个有关物质结构,IMP01为4-(1-甲基-5-吗啉-2-苯并咪唑基)丁酸盐酸盐,IMP02为4-{1-甲基-5-[(2-氯乙基)(2-羟乙基)氨基]-2-苯并咪唑基}丁酸盐酸盐。结果显示,在建立的LC-MS条件下,盐酸苯达莫司汀与其有关物质分离良好,通过分析鉴定有关物质结构,为其工艺和质量控制提供了参考依据。 In the HPLC analysis of bendamustine hydrochloride, two related substances( IMPO1 and IMP02) were detected. These two related substances were identified by LC-MS/MS and their structural confirmation was unam- biguously carried out by synthesis followed by characterization using Q-TOF/MS and NMR. Based on the spectral data, related substances IMP01 and IMP02 were characterized as 4-( 1-methyl-5-morpholino-lH-benzo[ d] imid- azol-2-yl) butyric acid hydrochloride and 4-{ 1-methyl-5-[ (2-chloroethyl) (2-hydroxyethyl) amino] -1H-benzol d] imidazol-2-yl) } butyric acid hydrochloride, respectively. Bendamustine hydrochloride and its related substances were separated under the established LC-MS condition. HPLC is a useful method for the determination of the related substances in bendamustine hydrochloride. Results obtained are valuable for its manufacturing process and quality control.
出处 《中国药科大学学报》 CAS CSCD 北大核心 2015年第3期333-338,共6页 Journal of China Pharmaceutical University
关键词 盐酸苯达莫司汀 有关物质 结构鉴定 含量测定 bendamustine hydrochloride related substances structural identification content determination
  • 相关文献

参考文献9

  • 1Cuneo A,Marchetti M,Barosi G,et al.Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia.Recommendations from SIE,SIES,GITMO Group[J].Leukemia Res,2014,38(11):1269-1277.
  • 2H?ffken K,Merkle KH,Sch?nfelder M,et al.Bendamustine as salvage treatment in patients with advanced progressive breast cancer:a phase II study[J].J Cancer Res Clin,1998,124(11):627-632.
  • 3Elefante A, Czuczman MS. Bendamustine for the treatment of indolent non-Hodgkin′s lymphoma and chronic lymphocytic leukemia[J].Am J Health Syst Pharm,2010,67(9):713-723.
  • 4P?nisch W,Dietger N.Bendamustine in the treatment of multiple myeloma:results and future perspectives[J].Semin Oncol,2002,29(4):23-26.
  • 5刘珍仁,叶晓岚,范国荣,张大志,黄景华.盐酸苯达莫司汀的电喷雾串联质谱分析[J].药学服务与研究,2012,12(6):414-417. 被引量:1
  • 6刘珍仁,叶晓岚,范国荣.盐酸苯达莫司汀临床给药过程中的降解产物及其结构确证[J].中国新药与临床杂志,2013,32(3):211-216. 被引量:5
  • 7Mathrusri AM,Venkatesh B,Anusha S,et al.Stability-indicating liquid chromatographic method for the determination of bendamustine hydrochloride in parenterals[J].Res J Chem Sci,2012,2(9):72-78.
  • 8汤浩,吴晓明,彭苏.HPLC法测定盐酸苯达莫司汀含量及有关物质[J].药学与临床研究,2009,17(4):303-305. 被引量:6
  • 9Kasa S,Reddy MRS.Stability-indicating LC method for the estimation of bendamustine hydrochloride and its related impurities[J].J Chromatogr Sci,2014,52(7):573-583.

二级参考文献26

  • 1Eichbaum M,Bischofs E,Nehls K,et al. Bendamustine hydro- chloride- a renaissance of alkylating strategies in anticancer medicine[J]. Drugs Today(Barc), 2009,45 (6) : 431-444.
  • 2National Cancer Institute. Cancer drug information: FDA ap- proval for bendamustine hydrochloride[EB/OL]. (2008-03-20) [2012-02-26]. http://www, cancer, gov/cancertopics/drugin- fo/fda-bendamustine-hydroehloride.
  • 3Schrijvers D,Vermorken J B. Phase Ⅰ studies with bendamus- tine., an update[J]. Semin Oncol, 2002,29 (4 Suppl 13) : 15- 18.
  • 4Chovan J P, Li Feng, Yu ErYa, et al. Metabolic profile of [^14C]bendamustine in rat urine and bile: preliminary structural identification of metabolites[J]. Drug Metab Dispos, 2007,35 (10) : 1744-1753.
  • 5Ogura M, Uchida T, Taniwaki M,etal. Phase I and pharma- cokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma[J]. Cancer Sci,2010,101(9) : 2054-2058.
  • 6Dennie T W, Kolesar J M. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indo- lent B-cell non-Hodgkin lymphoma[J]. Clin Ther, 2009,31 Pt 2:2290-2311.
  • 7Teichert J, Baumann F, Chao Q; et al. Characterization of two phase I metabolites of bendamustine in human liver mi- crosomes and in cancer patients treated with bendamustine hydrochloride[J]. Cancer Chemother Pharmacol,2007,59(6) : 759-770.
  • 8EICHBAUM M, BISCtlOFS E, NEHLS K, et ol. Bendamustinehydrochloride-a renaissance of alkylating strategies in anticancer medicine[J] Druzs of Todav. 2009. 45(6), 4-31-444.
  • 9BAMAN BALFOUR JA, GOA KL. Bendamustine [J]. Drugs, 2001, 61(5): 631-640.
  • 10WEIDE R. Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin's lymphoma[J]. Ther Clin Risk Manag, 2008, 4(4): 727-732.

共引文献8

同被引文献6

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部